Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
5
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
biotech
boston
drugs
fda
san francisco blog main
san francisco top stories
seattle blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
ipo
national
raleigh-durham blog main
raleigh-durham top stories
san francisco
seattle top stories
startups
texas blog main
texas top stories
vc
wisconsin blog main
wisconsin top stories
acetylon pharmaceuticals
akcea therapeutics
alder biopharmaceutical
allergan
What
make
5
×
big
drug
fda
medical
new
startup
way
acquisition
aiming
alnylam
amazon’s
ambys
approval
approves
arguments
biotech
biotechs
cells
ceo
chose
circulation
class
close
commercialized
companies
company
competitors
control
deadly
deal
debuted
decades
device
diseases
drugs
efficient
ema
emergency
employ
Language
Current search:
make
×
" boston top stories "
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Circulation CEO Talks Sale to LogistiCare & Amazon’s Healthcare Play
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
